InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-12-31 | James French Hill(R-AR02) | house | Sale | $15,001 - $50,000 |
| 2025-01-15 | Julie Johnson(D-TX32) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total net sales | $1.98B+3.7% | $1.91B+0.3% | $1.90B+3.9% | $1.83B |
| Gross profit | $4.45B-3.1% | $4.59B-2.1% | $4.69B-0.0% | $4.70B |
| Selling, general and administrative expenses | $3.08B+10.7% | $2.78B+21.0% | $2.30B+2.9% | $2.23B |
| Research and development expenses | $739.0M-4.6% | $775.0M+2.2% | $758.0M-1.2% | $767.0M |
| Gain on sale of business | -$1.55B | $0+100.0% | -$56.0M | — |
| Operating income | $2.18B+110.5% | $1.04B-38.8% | $1.69B-0.1% | $1.69B |
| Interest expense, net | $347.0M-5.4% | $367.0M | $0 | $0 |
| Loss on debt extinguishment, net | $82.0M | $0 | $0 | — |
| Other expense (income), net | $39.0M-39.1% | $64.0M+156.0% | $25.0M+2400.0% | $1.0M |
| Income before income taxes | $1.71B+183.1% | $605.0M-63.7% | $1.67B-1.5% | $1.69B |
| Provision for income taxes | $157.0M+23.6% | $127.0M-60.4% | $321.0M-8.0% | $349.0M |
| Net income | $1.56B+224.8% | $479.0M-64.4% | $1.35B+0.2% | $1.34B |
| Basic earnings per share (in dollars per share) | $8.9M+222.7% | $2.8M-64.4% | $7.8M+0.1% | $7.8M |
| Diluted earnings per share (in dollars per share) | $8.9M+221.7% | $2.8M-64.6% | $7.8M+0.1% | $7.8M |
| Basic (in shares) | $174.1M+0.5% | $173.2M+0.3% | $172.7M+0.0% | $172.7M |
| Diluted (in shares) | $175.3M+0.9% | $173.7M+0.6% | $172.7M+0.0% | $172.7M |
| Cost of product | ||||
| Total net sales | $1.98B+3.7% | $1.91B+0.3% | $1.90B+3.9% | $1.83B |
| Cost of sales | $472.0M-3.5% | $489.0M+1.7% | $481.0M-0.2% | $482.0M |
| Cost of software and rentals | ||||
| Total net sales | $1.98B+3.7% | $1.91B+0.3% | $1.90B+3.9% | $1.83B |
| Cost of sales | $472.0M-3.5% | $489.0M+1.7% | $481.0M-0.2% | $482.0M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
How The Solventum (SOLV) Narrative Is Shifting With Mixed Analyst Targets And Model Resets
Solventum gains after activist Trian sends letter urging changes (update)
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
CVS Q1 Earnings Preview: Health Services Likely to Lead Performance